A5075720331- Cancer Genomics and Diagnostics
- Extracellular vesicles in disease
- Lung Cancer Treatments and Mutations
- MicroRNA in disease regulation
- Innovative Microfluidic and Catalytic Techniques Innovation
- CRISPR and Genetic Engineering
- CAR-T cell therapy research
- Renal cell carcinoma treatment
- Cell Adhesion Molecules Research
- Evolution and Genetic Dynamics
- Radiomics and Machine Learning in Medical Imaging
- RNA Research and Splicing
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Plant Virus Research Studies
- Genomics and Chromatin Dynamics
- Mycobacterium research and diagnosis
- Cancer Immunotherapy and Biomarkers
- Lattice Boltzmann Simulation Studies
- Cancer-related molecular mechanisms research
Exosome Diagnostics (United States)
2017-2022
CS Diagnostics
2017
ETH Zurich
2010
European Molecular Biology Laboratory
2007
Exosomes and other extracellular vesicles (commonly referred to as EVs) have generated a lot of attention for their potential applications in both diagnostics therapeutics. The contents these are the subject intense research, relatively recent discovery RNA inside EVs has raised interest biological function RNAs well biomarkers cancer diseases. Traditional ultracentrifugation-based protocols isolate labor-intensive significant variability. Various attempts develop methods with robust,...
BackgroundA major limitation of circulating tumor DNA (ctDNA) for somatic mutation detection has been the low level ctDNA found in a subset cancer patients. We investigated whether using combined isolation exosomal RNA (exoRNA) and cell-free (cfDNA) could improve blood-based liquid biopsy EGFR non-small-cell lung (NSCLC) patients.Patients methodsMatched pretreatment plasma were collected from 84 patients enrolled TIGER-X (NCT01526928), phase 1/2 study rociletinib mutant NSCLC The isolated...
The Polycomb group (PcG) and Trithorax (TrxG) of proteins are required for stable heritable maintenance repressed active gene expression states. Their antagonistic function on control, repression PcG activity TrxG, is mediated by binding to chromatin subsequent epigenetic modification target loci. Despite our broad knowledge about composition enzymatic activities the protein complexes involved, understanding still lacks important mechanistic detail a comprehensive view genes. In this study...
Purpose: Blood-based liquid biopsies offer easy access to genomic material for molecular diagnostics in cancer. Commonly used cell-free DNA (cfDNA) originates from dying cells. Exosomal nucleic acids (exoNAs) originate living cells, which can better reflect underlying cancer biology.Experimental Design: Next-generation sequencing (NGS) was test exoNA, and droplet digital PCR (ddPCR) BEAMing were cfDNA BRAFV600, KRASG12/G13, EGFRexon19del/L858R mutations 43 patients with progressing advanced...
Extracellular RNAs (exRNAs) have been identified in all tested biofluids and associated with a variety of extracellular vesicles, ribonucleoprotein complexes lipoprotein complexes. Much the interest exRNAs lies fact that they may serve as signalling molecules between cells, their potential to biomarkers for prediction diagnosis disease possibility or particles carry them might be used therapeutic purposes. Among most significant bottlenecks progress this field is lack robust standardized...
Improved risk stratification of patients suspected prostate cancer prior to biopsy continues be an unmet clinical need. ExoDx Prostate (IntelliScore) "EPI" is a non-invasive urine test utilizing RNA from exosomes provide score that correlates with the likelihood finding high grade at biopsy. Here, we present results prospective validation study EPI-CE, CE-marked in-vitro diagnostic (IVD) assay, specifically developed for use in European laboratories. The (NCT04720599) enrolled ≥ 50 years,...
In addition to Circulating Tumour Cells (CTCs), cell-free DNA (cfDNA) and Extracellular Vesicles (EVs), the notion of "Tumour-Educated Platelets" (TEP) has recently emerged as a potential source tumour-derived biomarkers accessible through blood liquid biopsies. Here we sought confirm suitability platelet fraction for biomarker detection in comparison their corresponding EV fraction. As publications have claimed that tumour RNA other material are transferred from cells platelets transcripts...
Abstract The diagnostic potential of exosomes and extracellular vesicles (EVs) for liquid biopsies was first demonstrated over a decade ago, but despite lot progress in the scientific field there are still very few applications EVs that ready implementation clinical laboratories routine use. Despite good options isolation wide analyte target space assay development (incl. RNA, DNA, proteins intact EVs) assessable by standard detection technologies, attrition rate translating biomarker...
Exosomes and other small extracellular vesicles (EVs) are potential sources of cancer biomarkers. Plasma-derived EVs have not yet been studied in pediatric Hodgkin lymphoma (HL), for which predictive biomarkers relapse greatly needed. In this two-part proteomic study, we used two-dimensional difference gel electrophoresis (2D-DIGE) followed by liquid chromatography–tandem mass spectrometry (LC–MS/MS) to analyze EV proteins plasma collected at diagnosis from children with nodular sclerosis...
Abstract Introduction: The EML4-ALK (echinoderm microtubule-associated protein-like 4/anaplastic lymphoma kinase) translocation represents a predictive driver mutation in non-small cell lung cancer (NSCLC). As is both associated with resistance to EGFR inhibitors and druggability FDA approved ALK kinase inhibitors, molecular profiling of the respective fusion transcripts an important prerequisite for therapy. Ongoing clinical trials development new personalized treatment also emphasize need...
Abstract Background: After initial responses to tyrosine kinase inhibitors (TKIs), NSCLC patients (pts) harboring EGFR activating mutations inevitably progress, with the “gatekeeper” T790M resistance mutation accounting for approximately 60% of cases acquired (AR) TKIs. and can be found in plasma on both circulating free tumor DNA (ctDNA) RNA contained within exosomes. While ctDNA is thought primarily released by dying cells, exosome actively many living cells (Jahr et al. Cancer Res 2001;...
e24090 Background: Molecular profiling of mutations in NSCLC patients is increasing relevance for direction targeted therapy. Assessing such biomarkers directly from plasma overcomes hurdles associated with biopsies, including significant risk and difficulties to monitor molecular changes longitudinally. Here we applied testing detection EML4-ALK fusions ALK resistance exosomal nucleic acids lung cancer patients. In a prospective cohort ALK-positive the longitudinal monitoring response...
9017 Background: Oncogenic mutations in the BRAF gene (V600E/V600K) are present 40-50% of patients with MM and represent an important therapeutic target (e.g. vemurafenib). Blood-based, serial monitoring other during therapy may be useful to inform time-critical treatment decisions. Plasma contains at least two sources cell-free nucleic acids (NAs): exosomal RNA (exoRNA) DNA (cfDNA). Combining exoRNA cfDNA maximizes yield genetic material from plasma, enable both biologically enhance...
e22156 Background: Initial response to tyrosine kinase inhibitors (TKIs) in NSCLC patients with EGFR activating mutations are commonly observed, however inevitably progress as a consequence of acquired resistance (AR). Secondary the domains play role clinical substantial portion patients, and novel agents development this setting. Tissue based assays, requiring repeat biopsy, less attractive, detection AR circulation would be an appealing alternative. Here we present data demonstrating...
469 Background: The objective of the present study was to assess FGFR mutattions and fusions from matched urine tissue samples patients suspicious bladder cancer undergoing first TURB within BRIDGister RealWorld Experience trial. Methods: FFPE 39 pts participating in trial were prospectively collected analyzed. RNA tissues extracted by commercial kits analyzed Therascreen IVD kit (Qiagen GmbH, Hilden). In addition extracellular vesicles centrally isolated for subsequent extraction...
e16532 Background: The objective of the present study was to assess FGFR mutattions and fusions from matched urine tissue samples patients suspicious bladder cancer undergoing first TURB at pilot center multicentric BRIDGister RealWorld Experience trial Methods: For this paraffin fixed pretreatment 28 pts participating in were prospectively collected analyzed. RNA FFPE tissues extracted by commercial kits analyzed Therascreen IVD kit (Qiagen GmbH, Hilden). In addition shipped for central...
11061 Background: Circulating nucleic acids (NA) in the bloodstream of cancer patients are interest because their potential to provide tumor mutation status without requiring a tissue sample. Blood plasma contains at least two sources circulating cell-free NA: free DNA (cfDNA), from apoptotic/necrotic cells, and RNA enclosed exosomes (exoRNA), which secreted by living cells through active metabolic processes. However, derived mutated sequences often very low abundance against background...
<p>Supplementary File 1. Patients and treatment details</p>